शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
INNOVACAPNSEInnova Captab Limited· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Mon, 26 May, 2025 · 18:37 IST

Innova Captab Q4 FY25 earnings call transcript filed

Management guided margin improvementInvestor Communications View source PDFExplain this filing

INNOVACAP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.7%Reaction day
₹870.00
prior close
₹879.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-0.6% vs market
Pharmaceuticals peers, median of 147sector+0.1%-0.8% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.8
10m
-1.5
15m
-1.7
30m
-1.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.7-0.1-0.6+0.1-0.8
Next day
-2.2+0.2-2.4-0.0-2.2
2d
-0.2+0.6-0.8+0.8-1.1
3d
+0.3+0.9-0.6+0.3+0.0
4d
+1.6+1.0+0.6+0.0+1.6
5d
+2.6+0.7+1.9-0.7+3.3
1w
+1.9+1.8+0.2-0.1+2.0
15d
+1.0+1.7-0.7-0.9+1.9
1m
-1.1+3.1-4.2-0.6-0.6
2m
+0.6+1.7-1.1+0.4+0.2
3m
+3.8-1.0+4.8-3.0+6.8
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Innova Captab filed Q4 FY25 earnings call transcript. FY25 revenue grew 15% to INR 1,243.7 cr; PAT up 36% to INR 128.3 cr with margins expanding 160 bps to 10.3%. Q4 revenue rose 20% to INR 314.7 cr. New Jammu plant contributed INR 36 cr in Q4. Management guides Jammu at INR 400 cr in FY26 (includes INR 30-35 cr GST benefit) and targets 25% revenue CAGR over 3 years to INR 2,500 cr. Margins seen improving with operating leverage.

Likely market impact

Strong FY25 results with margin expansion. Jammu plant ramp-up and INR 2,500 cr 3-year revenue target signal strong growth visibility for shareholders.